New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA® (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
Business Wire•07/11/2026•10:00 ET
2
Key Highlights
- ➤16,322 veterans switched from HUMIRA to HADLIMA across the VA system
- ➤HADLIMA switchback rate was 1.3% over 12 months
- ➤Per-patient pharmacy costs fell $8,100 in the first year
- ➤VA system estimated $132 million in total savings
- ➤Adherence metrics remained similar before and after switching
Expert Statements
Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon
“The findings demonstrate that a well-managed formulary transition to HADLIMA can deliver both continuity of care and economic savings.”
Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon
“Real-world evidence at this scale is critical for showing that biosimilar adoption can support sustainable health systems while delivering confidence to doctors and patients alike.”
Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon
“At Organon, we believe in the potential of biosimilars to expand patient access to effective treatments while potentially reducing the affordability burden on health care systems.”
New Real-World Evidence Presented by Organon at the American College of Rheumatology (ACR) Annual Meeting Evaluated a Large-Scale Switch to HADLIMA(®) (adalimumab-bwwd) Across United States Veterans Affairs Healthcare System
* Analysis of over 16,000 patients switched to HADLIMA(®) from HUMIRA(®) (adalimumab) showed a 1.3% switchback rate over a 12-month follow-up period(1)
Get started
Create a free account to read the full story.